Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

HLB’s Lirafugratinib Advances to European Review After U.S. Approval

Following its U.S. approval, HLB’s cholangiocarcinoma drug lirafugratinib has entered formal regulatory review for European market entry. About two weeks after receiving approval from the U.S. Food and Drug Administration (FDA), the drug has moved into the formal marketing authorization review proce

We haven't written up this one. BusinessKorea has the full story — the link below goes straight to it.

Read the original at businesskorea.co.kr →

More in Health & Medicine

More from Wednesday 7 October →